PITTSBURGH–(BUSINESS WIRE)–April 20, 2006–News From DSFV: DuPont’s (NYSE:DD) continued use of the chemical perfluorooctanoic acid (PFOA) keeps the company at financial risk, concludes a report ...
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
Forty-six pretreated patients with CD22+ non-Hodgkin's lymphoma (NHL; n = 4), chronic lymphocytic leukemia (CLL; n = 11), and hairy cell leukemia (HCL; n = 31) received 265 cycles at 3 to 50 μg/Kg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results